Figure 1 (Hisun Ticagrelor 01)
Ticagrelor Tablet, Film Coated
Product Images NDC 42658-115
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 42658-115). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hisun Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2 (Hisun Ticagrelor 02)
Chemical Structure (Hisun Ticagrelor 03)
Figure 3 (Hisun Ticagrelor 04)
Figure 4 (Hisun Ticagrelor 05)
Figure 6 (Hisun Ticagrelor 07)
This text provides information about interacting drugs and their effects, along with recommendations for doses and adjustments based on strong CYP3A4 inhibitors, moderate CYP3A4 inhibitors, and potent CYP3A inducers. It also mentions specific drugs like aspirin, desmopressin, heparin, enoxaparin, cyclosporine, morphine, and fentanyl, and advises on dose adjustments for concomitant use. The text also includes data related to PK parameters such as Cmax and AUC.*
Figure 7 (Hisun Ticagrelor 08)
This text provides information on the interactions of Ticagrelor with different drugs such as Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine. It includes details on recommended dose adjustments for Ticagrelor based on the co-administration of these drugs. The text provides insights on the mean effect and 90% confidence intervals for these drug interactions, helping healthcare professionals make informed decisions regarding medication regimens.*
Figure 8 (Hisun Ticagrelor 09)
This text provides information about a cumulative percentage of 109%. The value 1014 represents 19.7% of a total value.*
Figure 9 (Hisun Ticagrelor 10)
This text appears to be a statistical analysis report displaying various characteristics and results of a treatment intervention study. The data includes percentages for different geographic regions, treatment approaches, medication dosage, planned treatment approaches, and outcomes related to two different drugs - Ticagrelor and Clopidogrel. The report also provides information on demographic factors like age, sex, and race. Additionally, it includes hazard ratios and confidence intervals for various comparisons. Overall, the text offers a detailed summary of the study findings.*
Figure 10 (Hisun Ticagrelor 11)
Figure 11 (Hisun Ticagrelor 12)
This is a statistical analysis of a study comparing the effectiveness of a medication called Ticagrelor with a placebo in patients. The study involved 7050 patients taking Ticagrelor, 7045 patients on a placebo, and tracked events over a period of time. The results show the hazard ratio, confidence intervals, and Kaplan-Meier estimates. The data is presented in a table format with the number of patients at risk over a specific period of days from randomization.*
Figure 12 (Hisun Ticagrelor 13)
Ticagrelor Tablets 90 mg 60 Count Bottle Label (Hisun Ticagrelor 14)
This is a label of Ticagrelor tablets with a lot number, expiration date, and barcode information. The medication guide should be given to each patient. The tablets contain 90 mg of Ticagrelor, and storage instructions are provided. The tablets are distributed by Hisun Pharmaceuticals USA, Inc. and manufactured in China.*
15 (Hisun Ticagrelor 15)
16 (Hisun Ticagrelor 16)
17 (Hisun Ticagrelor 17)
18 (Hisun Ticagrelor 18)
19 (Hisun Ticagrelor 19)
20 (Hisun Ticagrelor 20)
21 (Hisun Ticagrelor 21)
This text appears to be a table showing recommendations for Ticagrelor AR-C124010XX based on intrinsic factors such as age, gender, ethnicity, renal impairment, end-stage renal disease, and hepatic impairment. It suggests dose adjustments or no adjustments based on these factors. Additionally, it mentions that a single dose of BRILINTA is administered for 3 days without any specific recommendations for patients with end-stage renal disease on hemodialysis.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
